Blueprint Medicines initiated with a Neutral at UBS

UBS initiated coverage of Blueprint Medicines (BPMC) with a Neutral rating and $88 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. The analyst says Ayvakit’s opportunity is largely priced into shares of Blueprint.